^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    medroxyprogesterone

    Company:
    Generic mfg.
    Drug class:
    Progesterone receptor agonist
    Related drugs:
    4d
    Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov)
    P=N/A, N=320, Not yet recruiting, Weill Medical College of Cornell University | Initiation date: Oct 2025 --> Jan 2026 | Trial primary completion date: Jan 2028 --> Sep 2029
    Trial initiation date • Trial primary completion date
    |
    medroxyprogesterone
    7d
    SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov)
    P3, N=207, Recruiting, Bayer | Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2027 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    medroxyprogesterone
    1m
    Medroxyprogesterone Acetate Inhibits Tumorigenesis in Mouse Models of Oviductal High-Grade Serous Carcinoma. (PubMed, Cancers (Basel))
    These findings demonstrate that a synthetic progestin, specifically MPA, confers robust protection against HGSC development, while a combination including E2 (E2 + P4) increases risk. This work also illustrates how HGSC GEMMs can be used to compare the chemo-preventive effects of various synthetic progestins on HGSC development in order to prioritize the most effective ones for use in preventing HGSC in both general and high-risk populations.
    Preclinical • Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1)
    |
    medroxyprogesterone
    1m
    SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov)
    P3, N=207, Not yet recruiting, Bayer | N=300 --> 207
    Enrollment change
    |
    medroxyprogesterone
    3ms
    Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov)
    P=N/A, N=320, Not yet recruiting, Weill Medical College of Cornell University | Initiation date: Jun 2025 --> Oct 2025
    Trial initiation date
    |
    medroxyprogesterone
    3ms
    Long-term disease-free survival after bilateral video-assisted thoracoscopic resection of multiple pulmonary metastases from endometrial stromal sarcoma: An 8-year follow-up case report. (PubMed, Gynecol Oncol Rep)
    The patient received oral medroxyprogesterone acetate for five years...She remains disease-free a total of eight years after metastasectomy. Complete resection of bilateral multiple pulmonary metastases from LG-ESS, combined with hormonal therapy, can achieve durable long-term disease control in carefully selected patients.
    Journal • Video
    |
    PGR (Progesterone receptor) • MME (Membrane Metalloendopeptidase)
    |
    PGR positive
    |
    medroxyprogesterone
    3ms
    Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease. (PubMed, Gynecol Oncol)
    These findings not only provide a foundation for identifying effective biomarkers for MPA efficacy, but also reveal deeper insights into the mechanism of action of progestins.
    Journal • Tumor mutational burden
    |
    PGR (Progesterone receptor) • TMB (Tumor Mutational Burden)
    |
    medroxyprogesterone
    4ms
    RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov)
    P4, N=250, Active, not recruiting, University of British Columbia | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    medroxyprogesterone
    4ms
    Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov)
    P3, N=126, Not yet recruiting, The First Affiliated Hospital of Xinxiang Medical College
    New P3 trial
    |
    megestrol • medroxyprogesterone • fosaprepitant • ondansetron
    5ms
    Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, Peking University People's Hospital | Trial completion date: Jun 2027 --> Dec 2027 | Initiation date: Apr 2025 --> Jul 2025
    Trial completion date • Trial initiation date
    |
    medroxyprogesterone
    6ms
    Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov)
    P=N/A, N=320, Not yet recruiting, Weill Medical College of Cornell University
    New trial
    |
    medroxyprogesterone
    8ms
    Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov)
    P2, N=38, Recruiting, Peking University People's Hospital | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    medroxyprogesterone • atorvastatin